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http://dx.doi.org/10.1016/j.kjms.201Abstract IgA nephropathy (nephropathy with mesangial IgA and IgG deposits, so-called Ber-
ger’s disease) is the most common primary chronic glomerulonephritis worldwide, and was first
described in 1968. Histopathologically, IgA nephropathy is characterized by expansion of the
glomerular mesangial matrix with mesangial cell proliferation and/or mononuclear cell infiltra-
tion. Glomeruli typically contain generalized-diffuse granular mesangial deposits of IgA
(mainly IgA1), IgG and C3. This disease, therefore, is considered to be an immune-complex-
mediated glomerulonephritis although the antigenic agents are still obscure. Clinically,
patients with IgA nephropathy show microscopic and macroscopic hematuria and/or protein-
uria. Although the clinical course is generally gradual in patients with IgA nephropathy,
progression to renal hypertension, renal anemia, and end-stage kidney disease is not as rare
as originally thought. Since pathogenesis and radical treatment for IgA nephropathy are still
not established, it is necessary to study them using various clinical findings.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
IgA nephropathy is the most common primary chronic
glomerulonephritis worldwide, and was first described by
J. Berger et al. in 1968 [1]. Glomeruli typically contain
generalized-diffuse granularmesangial deposits of IgA (mainly
IgA1), IgG, and C3 (Fig. 1A). IgA nephropathy is generally
considered to be an immune-complex-mediated glomerulo-
nephritis. Clinically, patients with IgA nephropathy showt of Internal Medicine, Jun-
e, 2-1-1 Hongo, Bunkyo-Ku,
.jp.
vier Taiwan LLC. All rights reserv
2.04.012microscopic and macroscopic hematuria and/or proteinuria.
The majority of patients show no symptoms, but occasionally
acutenephritic syndromeoccurs. Theoccurrenceofnephrotic
syndrome is relatively rare, however. Although the clinical
course is generally gradual in patients with IgA nephropathy,
progression to renal hypertension, renal anemia, and end-
stage kidney disease (ESKD) is not as rare as originally
thought. Earlymedical interventionmay lead to a better renal
prognosis, particularly for the those with a relatively poor
prognosis according to the Japanese Guidelines, who repre-
sent amajor portion of the IgA nephropathy population. Thus,
it appears that early diagnostic screening and subsequent
intervention are important for a good prognosis in IgA
nephropathy patients [2].ed.
Figure 1. Histology of nephropathy: (A) immunofluorescence (left: IgA, right: C3); (B) light microscopy (PAS staining, arrow;
para- mesangial deposits); (C) light microscopy (PAS staining, advanced stage); (D) electron microscopy.
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of prognosis in IgA nephropathy based on clinicopatholog-
ical findings.
Clinical predictors of prognosis in patients with
IgA nephropathy
Clinical markers for poor prognosis in this disease are as
follows: (1) heavy proteinuria; (2) mild hematuria; (3) low
serum albumin; (4) renal dysfunction at the time of renal
biopsy; (5) diastolic hypertension; (6) male sex; and (7) age
below 30 years [3]. The total numbers of each type of urinary
cast in the urinary sediments should provide highly
convincing data for prediction of the prognosis in IgA
nephropathy patients prior to renal biopsy [4]. Many dys-
morphic red blood cells (RBCs), various cellular casts, and
activated platelets in the urinary sediments are frequently
observed in theadvanced stageof this disease [4,5] (Table 1).Table 1 Clinical predictors of prognosis in IgA
nephropathy.
1) Heavy proteinuria
2) Mild hematuria
3) Low serum albumin
4) Renal dysfunction at the time of renal biopsy
5) Diastolic hypertension
6) Male sex
7) Age below 30 years
8) Urinary findings: many dysmorphic red blood cells,
various cellular casts, IL-6, MCP-1
9) Serum IgA/C3 ratio: complement activationNo essential blood chemistry findings are characteristic of
this disease although serum IgA of >3.15 g/L has frequently
been observed in adult patients with IgA nephropathy.
Furthermore, levels of urinary IL-6, a T-cell-derived
lymphokine,andMCP-1,a chemotactic protein formonocytes
and T cells, are marked in the advanced stage of IgA
nephropathy, which is characterized by severe proliferative
glomerular changes. Measurement of urinary IL-6 and MCP-1
is useful for evaluating the degree of glomerular injuries and/
or prognosis in patients with IgA nephropathy [6,7]. We have
already reported the importance of four clinical markers in
the diagnosis of patients with IgA nephropathy or in differ-
ential diagnosis from other types of chronic glomerulone-
phritis as follows [4,5]: (1) more than five RBCs in urinary
sediments; (2) persistent proteinuria (urinary protein of
>0.3 g/day); (3) serum IgA level of >3.15 g/L; and (4) serum
IgA/complement 3 (C3) ratio of >3.01. Since the serum IgA/
C3 ratio decreases with improvement of proteinuria and/or
hematuria, a high ratio might be one of the prognostic
markers in this disease (Ohsawa et al. unpublished data).
However, the prognostic significance of gene polymorphisms
of the renin angiotensin system such as ACE genotype is still
controversial in patients with IgA nephropathy.
In Japan, about 70% of IgA nephropathy cases are revealed
by abnormalities in urinalysis performed during annual
medical check-ups in schools or offices. A Joint Committee of
the Special Study Group on Progressive Glomerular Disease,
Ministry of Health, Labor and Welfare of Japan, and the
Japanese Society of Nephrology found in 1995 that it required
more than3 years onaverage fromestimatedonset to thefirst
consultation and subsequent diagnosis as IgA nephropathy by
renal biopsy [8]. About 30% and 5% to 10% of IgA nephropathy
patients develop ESKD within 15% to 20 years and 5 years,
respectively. Conversely, about 60% can avoid ESKD.
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Histological grading
Histopathologically, IgA nephropathy is characterized by
expansion of glomerular mesangial matrix with mesangial
cell proliferation and/or mononuclear cell infiltration
(Fig. 1). Paramesangial deposits and electron dense
deposits are also observed in the glomeruli Fig. 1B and
1D). The histological marker for poor prognosis of IgA
nephropathy is generally considered to be glomerular
and/or tubulointerstitial injury (Fig. 1C). Among
numerous histologic grading systems for predicting renal
outcome of this disease, the recently published Oxford
classification identifies prognostic pathologic features,
providing substantial evidence that histologic grading
systems can be used to predict renal outcome of IgA
nephropathy [9]. When developing a histological classifi-
cation of IgA nephropathy, some issues need to be
considered. In Japan, the Special IgA Nephropathy Study
Group of the Progressive Renal Diseases Study Committee
organized by the Ministry of Health, Labor and Welfare
conducted a multicenter retrospective case-control study
on IgA nephropathy in 2004 to develop an evidence- and
lumped-system-based clinicopathological classification of
IgA nephropathy for predicting long-term risk of progres-
sion to ESKD [10]. The study enrolled 287 patients with
a median follow-up of 9.3 years (range 0.7e34.0 years)
after renal biopsy. During follow-up, 49 patients (19%)
progressed to ESKD. Multivariate logistic regression anal-
ysis showed that the independent pathological variables
that predicted progression to ESKD were global sclerosis,
segmental sclerosis, and fibrous crescents for patients
who progressed to ESKD within 5 years after biopsy, and
global sclerosis and cellular/fibrocellular crescents for
those who progressed to ESKD within 5 to 10 years after
biopsy. Four histological grades (HG), i.e., HG 1, HG 2, HG
3, and HG 4, were established corresponding to <25%, 25%
to 49%, 50% to 74%, and 75% of glomeruli exhibiting
cellular or fibrocellular crescents, global sclerosis,
segmental sclerosis, or fibrous crescents. Eleven (7%)
patients in HG 1, 12 (16%) in HG 2, 13 (31%) in HG 3 and 13
(68%) in HG 4 progressed to ESKD. Multivariate logistic
analysis revealed that the risk of progression to ESKD was
significantly higher in HG 2, 3 and 4 than in HG 1 (odds
ratios: 2.4, 5.7 and 27.6 vs. 1.0). It appears that this
evidence- and lumped-system-based histological classifi-
cation can identify the magnitude of the risk of diseaseTable 2 Histopathological predictors of prognosis in IgA
nephropathy.
1) Glomerular and tubulointerstitial injuries
2) Expressions of glomerular cytokines and/or extracellular
matrices
3) Podocyte injury (podocytopenia)
4) Mast cell infiltration in the interstitium
5) Othersprogression and is useful for predicting long-term renal
outcome in patients with IgA nephropathy [10] (Table 2).
Glomerular cytokine expression
Several cytokines and/or growth factors, such as interleukin
(IL)-1, IL-2, IL-6, tumor necrosis factor-a (TNFa), platelet-
derived growth factor and transforming growth factor-b,
have been shown to be involved in glomerular mesangial cell
proliferation and hyperproduction of extracellular matrices,
i.e. fibronectin, type IV collagen, and laminin. Intercellular
adhesion molecule-1 (ICAM-1), a glycoprotein of 90 kD to 110
kD, which belongs to the immunoglobulin superfamily, is
a lymphokine, i.e. IL-1-, TNFa and/or interferon-a-inducible
cell-surface molecule. Using immunofluorescence, the
authors examined patients with IgA nephropathy to deter-
mine whether the expression of ICAM-1 in glomeruli might
reflect disease activity. Glomeruli that showed increases of
ICAM-1 expression had marked infiltration of lymphocytes
and monocytes. The average number of these cells in
glomeruli was increased in advanced-stage patients who
showed an increase of ICAM-1 expression in the glomeruli. It
appears that the expression of ICAM-1 is closely linked to
glomerular cell infiltration of lymphocytes and monocytes in
patients with IgA nephropathy [11].
Podocyte injury
The number of podocytes per glomerulus should serve as
a podocyte injury parameter and provide prognostic infor-
mation in patients with IgA nephropathy. Development of
glomerulosclerosis in IgA nephropathy patients is associated
with podocyte injury, which may be caused by apoptosis,
necrosis, detachment from the glomerular basement
membrane (GBM) or autophagy of these cells. Podocytes in
adults do not undergo mitosis, and normally the only way to
respond to injury is by cell hypertrophy. Thus, increased
podocyte surface area reflects the extent of podocyte
hypertrophy. In severe patients, segments of the GBM
become denuded. Direct contact of the naked portion of
the GBM with the parietal epithelium of Bowman’s capsule
might lead to adhesion to Bowman’s capsule and poten-
tially to segmental sclerosis [12].
Lemley et al. [13] reported that podocyte loss, i.e.
podocytopenia, is concurrent with increasing disease
severity in patients with IgA nephropathy. They observed no
corresponding correlations between the clinical indices of
injury and the number of mesangial and endothelial cells in
this disease. Endothelial and mesangial cell damage is fol-
lowed by regeneration, but this is not the case with podo-
cytes. Hishiki et al. [14] also reported that podocyte injuries
e i.e. reduction of absolute number per glomerulus and
increase of glomerular surface area covered by one podo-
cyteewere related to the progression of disease in patients
with IgA nephropathy. Thus, podocyte injury might provide
additional prognostic information about for such patients.
Dendrin, which is a novel component of the glomerular
slit diaphragm, accumulates in the nucleus of injured
podocytes in experimental nephritis. Recently, Kodama
et al. investigated the presence of nuclear dendrin and the
relationship between relocation of dendrin to the podocyte
520 Y. Tominonucleus and disease progression in patients with IgA
nephropathy. A positive correlation was observed between
acute extracapillary changes and the number of dendrin
positive nuclei per glomerulus. It appears that the number
of dendrin positive nuclei in renal biopsy specimens is
useful in evaluation of disease activity in patients with IgA
nephropathy (unpublished data).
Mast cell infiltration in the interstitium
Mast cells are derived from hematopoietic progenitors and
migrate into inflammatory lesions. Human mast cells can be
classified into two types according to their protease
composition: those containing only tryptase (MCT) and those
containing both tryptase and chymase (MCTC). MCT are
involved in immunological responses, whereas MCTC seem
instead to play a role in angiogenesis and tissue remodeling.
Some reports have suggested that mast cells play an
important role in the development of fibrosis and the
degradation of extracellular matrices. Kurusu et al. [15]
reported that the number of MCT in the fibrotic and non-
fibrotic areas may be one of the predictive factors for the
prognosis of patients with IgA nephropathy. Sakamoto-Ihara
et al. [16] also reported that IgA nephropathy patients had
more MCTC than MCT in the interstitial lesions. Mast cells
were observed around but not in the conglomerate of
angiotensin II (Ang-II)-positive cells. The number of Ang-II-
positive cells was correlated with MCTC and MCT in
patients with IgA nephropathy with the most severe patho-
logical changes. It appears that chymase-dependent Ang-II
synthesis due to human mast cells may be involved in the
inflammatory and fibrotic processes of IgA nephropathy [16].
Conclusion and future perspectives
Although the clinical course is generally gradual in patients
with IgA nephropathy, progression to renal hypertension,
renal anemia and ESKD is not as rare as was originally
thought. There are several clinical and pathological
predictors of the prognosis of this disease. Thus, it is sug-
gested that early diagnostic screening of prognosis predic-
tors and subsequent intervention are important for good
prognosis in patients with IgA nephropathy.
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